Cargando…

Percutaneous cryoablation for the treatment of extra‐abdominal desmoid tumors

BACKGROUND: Desmoid tumors are rare locally invasive, benign neoplasms that develop along aponeurotic structures. Current treatment is complicated by associated morbidity and high recurrence rates. METHODS: A retrospective, single‐institution review identified 23 patients (age: 16‐77) with extra‐abd...

Descripción completa

Detalles Bibliográficos
Autores principales: Redifer Tremblay, Kaila, Lea, William B., Neilson, John C., King, David M., Tutton, Sean M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6790665/
https://www.ncbi.nlm.nih.gov/pubmed/31236956
http://dx.doi.org/10.1002/jso.25597
_version_ 1783458819801612288
author Redifer Tremblay, Kaila
Lea, William B.
Neilson, John C.
King, David M.
Tutton, Sean M.
author_facet Redifer Tremblay, Kaila
Lea, William B.
Neilson, John C.
King, David M.
Tutton, Sean M.
author_sort Redifer Tremblay, Kaila
collection PubMed
description BACKGROUND: Desmoid tumors are rare locally invasive, benign neoplasms that develop along aponeurotic structures. Current treatment is complicated by associated morbidity and high recurrence rates. METHODS: A retrospective, single‐institution review identified 23 patients (age: 16‐77) with extra‐abdominal desmoid tumors who received CT‐guided percutaneous cryoablation as either a first‐line (61%) or salvage (39%) treatment in 30 sessions between 2014 and 2018. Median maximal lesion diameter was 69 mm (range: 11‐209). Intent was curative in 52% and palliative in 48%. Contrast‐enhanced cross‐sectional imaging was obtained before and after treatment in addition to routine clinical follow‐up. RESULTS: Technical success was achieved in all patients. The median follow‐up was 15.4 months (3.5‐43.4). Symptomatic improvement was demonstrated in 89% of patients. At 12 months, the average change in viable volume was  −80% (range −100% to  + 10%) and response by modified response evaluation criteria in solid tumors (mRECIST) was CR 36%, PR 36%, and SD 28% No rapid postablation growth or track seeding was observed. Four patients underwent repeat cryoablation for either residual or recurrent disease. Two patients sustained a major procedural complication consisting of significant neuropraxia. CONCLUSION: Cryoablation for desmoid tumors demonstrates a high degree of symptom improvement and local tumor control on early follow‐up imaging with relatively low morbidity.
format Online
Article
Text
id pubmed-6790665
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-67906652019-10-18 Percutaneous cryoablation for the treatment of extra‐abdominal desmoid tumors Redifer Tremblay, Kaila Lea, William B. Neilson, John C. King, David M. Tutton, Sean M. J Surg Oncol Research Articles BACKGROUND: Desmoid tumors are rare locally invasive, benign neoplasms that develop along aponeurotic structures. Current treatment is complicated by associated morbidity and high recurrence rates. METHODS: A retrospective, single‐institution review identified 23 patients (age: 16‐77) with extra‐abdominal desmoid tumors who received CT‐guided percutaneous cryoablation as either a first‐line (61%) or salvage (39%) treatment in 30 sessions between 2014 and 2018. Median maximal lesion diameter was 69 mm (range: 11‐209). Intent was curative in 52% and palliative in 48%. Contrast‐enhanced cross‐sectional imaging was obtained before and after treatment in addition to routine clinical follow‐up. RESULTS: Technical success was achieved in all patients. The median follow‐up was 15.4 months (3.5‐43.4). Symptomatic improvement was demonstrated in 89% of patients. At 12 months, the average change in viable volume was  −80% (range −100% to  + 10%) and response by modified response evaluation criteria in solid tumors (mRECIST) was CR 36%, PR 36%, and SD 28% No rapid postablation growth or track seeding was observed. Four patients underwent repeat cryoablation for either residual or recurrent disease. Two patients sustained a major procedural complication consisting of significant neuropraxia. CONCLUSION: Cryoablation for desmoid tumors demonstrates a high degree of symptom improvement and local tumor control on early follow‐up imaging with relatively low morbidity. John Wiley and Sons Inc. 2019-06-24 2019-09-01 /pmc/articles/PMC6790665/ /pubmed/31236956 http://dx.doi.org/10.1002/jso.25597 Text en © 2019 The Authors. Journal of Surgical Oncology Published by Wiley Periodicals, Inc. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Research Articles
Redifer Tremblay, Kaila
Lea, William B.
Neilson, John C.
King, David M.
Tutton, Sean M.
Percutaneous cryoablation for the treatment of extra‐abdominal desmoid tumors
title Percutaneous cryoablation for the treatment of extra‐abdominal desmoid tumors
title_full Percutaneous cryoablation for the treatment of extra‐abdominal desmoid tumors
title_fullStr Percutaneous cryoablation for the treatment of extra‐abdominal desmoid tumors
title_full_unstemmed Percutaneous cryoablation for the treatment of extra‐abdominal desmoid tumors
title_short Percutaneous cryoablation for the treatment of extra‐abdominal desmoid tumors
title_sort percutaneous cryoablation for the treatment of extra‐abdominal desmoid tumors
topic Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6790665/
https://www.ncbi.nlm.nih.gov/pubmed/31236956
http://dx.doi.org/10.1002/jso.25597
work_keys_str_mv AT redifertremblaykaila percutaneouscryoablationforthetreatmentofextraabdominaldesmoidtumors
AT leawilliamb percutaneouscryoablationforthetreatmentofextraabdominaldesmoidtumors
AT neilsonjohnc percutaneouscryoablationforthetreatmentofextraabdominaldesmoidtumors
AT kingdavidm percutaneouscryoablationforthetreatmentofextraabdominaldesmoidtumors
AT tuttonseanm percutaneouscryoablationforthetreatmentofextraabdominaldesmoidtumors